Combination targeted adjuvant therapy doubles relapse-free survival in stage III melanoma

(European Society for Medical Oncology) Combination targeted adjuvant therapy with dabrafenib and trametinib doubles relapse-free survival in patients with stage III BRAF-mutant melanoma, according to late-breaking results from the COMBI-AD trial presented today at the ESMO 2017 Congress in Madrid and published in the New England Journal of Medicine.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news